After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small cell lung cancer (NSCLC).
The news comes shortly after Roche released results showing that a combination ofTecentriq and Avastin, in addition to carboplatin and paclitaxel, was able to improve overall survival (OS).
Original Article: Tecentriq third time lucky after NICE nod in lung cancer